What did the FDA decide about Moderna's flu shot?
How regulators and the company moved from refusal to review
Regulators initially told the company they would not accept Moderna’s application for an mRNA influenza vaccine, citing concerns about the design of the trial used to support approval — in particular the choice of comparator and whether the study met the agency’s standards for an ‘‘adequate and well‑controlled’’ trial. That decision sparked immediate alarm across the vaccine industry and criticism from some experts who warned it could chill investment in next‑generation shots.
After further discussions between Moderna and the Food and Drug Administration, agency officials reversed course and agreed to review the company’s submission. The back-and-forth underscores both technical and political tensions within the agency and highlights the high stakes for manufacturers developing new vaccine platforms.
Why the episode matters
- It sets a precedent for how regulators will evaluate mRNA and other novel vaccine technologies against established standards.
- It may delay the timeline for wider use of this specific influenza product while the FDA completes its review.
- The dispute has broader implications for industry confidence and for public trust in regulatory decisions, especially as some stakeholders framed the initial refusal as politically influenced.
Next steps to watch
- The FDA’s formal review outcome and any requests for additional data or new trials.
- Whether the agency issues guidance clarifying acceptable comparators and trial designs for future mRNA vaccines.
- Industry responses, including whether other developers alter trial designs to avoid similar scrutiny.
For clinicians and patients, the immediate takeaway is that the vaccine’s availability may be delayed until the FDA completes its review and either approves the product or identifies gaps that Moderna must address.